Actinic Keratosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for actinic keratosis. 77 active patents protecting 5 drugs from 4+ originators. First major cliff: 2026. Daily refresh.

5
Approved drugs
77
Active US patents
64/100
Avg vulnerability
—
Annual revenue covered

Originators in Actinic Keratosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 24 patents Hisamitsu Pharmaceutical Co., Inc 14 patents Bausch Health 10 patents Almirall 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating actinic keratosis. Each bar = one year. Y-axis scaled to peak year (20 patents).

20
26
15
27
1
28
17
29
20
30
1
33
3
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Picato
INGENOL MEBUTATE
 Leo Labs 23 71 — 2026-12-18
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Aldara
IMIQUIMOD
 Bausch Health 10 73 — 2029-08-18
Klisyri
TIRBANIBULIN
 Almirall 6 46 — 2027-12-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8716271 Picato method of use 85 2026-12-18
8735375 Picato method of use 85 2026-12-18
8536163 Picato method of use 85 2026-12-18
8735375 Picato method of use 85 2026-12-18
8536163 Picato method of use 85 2026-12-18
8716271 Picato method of use 85 2026-12-18
11850245 Aldara method of use 81 2030-04-30
9820959 Picato method of use 80 2026-12-18
9861603 Picato method of use 80 2026-12-18
9820959 Picato method of use 80 2026-12-18

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10669236 Klisyri composition of matter 4 2038-09-07
7300931 Klisyri composition of matter 10 2030-12-28
9180096 Voltaren formulation 48 2030-04-23
9017721 Voltaren formulation 48 2030-04-23
9173854 Voltaren formulation 48 2030-04-23
9017721 Voltaren formulation 48 2030-04-23
9173854 Voltaren formulation 48 2030-04-23
9180096 Voltaren formulation 48 2030-04-23
8679544 Voltaren formulation 53 2030-04-23
8679544 Voltaren formulation 53 2030-04-23

Related